Evidence of CYP3A Allosterism In Vivo: Analysis of Interaction Between Fluconazole and Midazolam

Publisher： John Wiley & Sons Inc

E-ISSN： 1532-6535|91|3|442-449

ISSN： 0009-9236

Source： CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.91, Iss.3, 2012-03, pp. : 442-449

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Involvement of CYP 3A5 In the Interaction Between Tacrolimus and Nicardipine: A Case Report

By  

Current Drug Safety, Vol. 10, Iss. 3, 2015-01 ,pp. : 254-256

Bentham Science Publishers

Access to resources Recommend Favorite

A Nanogram Dose of the CYP3A Probe Substrate Midazolam to Evaluate Drug Interactions

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 93, Iss. 6, 2013-06 ,pp. : 564-571

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effect of brivaracetam on CYP3A activity, measured by oral midazolam

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 5, 2015-05 ,pp. : 543-548

John Wiley & Sons Inc

Access to resources Recommend Favorite

Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β‐hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese

By  

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 41, Iss. 5, 2016-10 ,pp. : 552-558

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluation of Endogenous Metabolic Markers of Hepatic CYP3A Activity Using Metabolic Profiling and Midazolam Clearance

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 94, Iss. 5, 2013-11 ,pp. : 601-609

John Wiley & Sons Inc

Access to resources Recommend Favorite